Table 1.
Clinicopathological characteristics of recurrent pancreatic cancer patients with sarcopenia and without sarcopenia
| Characteristics | Sarcopenia group (n = 65) | Non-sarcopenia group (n = 9) | P value |
|---|---|---|---|
| Age at time of recurrence, year, median (range) | 73.0 (44–85) | 68.0 (53–80) | 0.529 |
| Sex, male (n, %) | 44 (67.7%) | 5 (55.6%) | 0.476 |
| Body mass index at the time of recurrence, median (range), kg/m2 | 18.9 (13.3–26.8) | 23.4 (19.3–27.9) | < 0.001 |
| Primary tumor location (pancreatic head, %) | 42 (64.6%) | 6 (66.7%) | 1.000 |
| Primary tumor size, median (range), mm | 28.0 (5–60) | 30.0 (25–35) | 0.466 |
| Lymph node involvement (present, %) | 45 (69.2%) | 7 (77.8%) | 0.716 |
| Histological grading (G1a, %) | 30 (46.2%) | 6 (66.7%) | 0.302 |
| Time to recurrence after pancreatectomy (< 12 months, %) | 25 (38.5%) | 5 (55.6%) | 0.471 |
| Lymphatic vessel invasion (present, %) | 23 (35.9%) | 7 (77.8%) | 0.027 |
| Blood vessel invasion (present, %) | 27 (41.5%) | 6 (66.7%) | 0.176 |
| Perineural invasion (present, %) | 9 (13.8%) | 2 (22.2%) | 0.615 |
| Initial site of recurrence (distant, %) | 41 (63.1%) | 5 (55.6%) | 0.722 |
| Chemotherapy after recurrence (present, %) | 49 (75.4%) | 8 (88.9%) | 0.675 |
| Neutrophil-lymphocyte ratio, median (range) | 1.94 (0.36–18.60) | 1.62 (0.26–2.63) | 0.378 |
| Serum CA19-9 levels at time of recurrence, median (range), U/ml | 206.5 (0.1–20,460) | 92.1 (10.2–1843) | 0.669 |
Continuous variables are expressed as the median and range
CA19-9 carbohydrate antigen 19-9
aG1, well-differentiated